Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

This trial tests a new drug called RGT-61159 in adults with two specific types of cancer that have come back or stopped responding to treatment: adenoid cystic carcinoma (a rare cancer often found in salivary glands) and colorectal cancer (bowel cancer). **You may be eligible if...** - You have confirmed adenoid cystic carcinoma (ACC) or colorectal carcinoma (CRC) that has relapsed or is no longer responding to treatment - Your cancer has progressed on prior therapies and at least one measurable tumor is visible on scans - You have not had major surgery, chemotherapy, or radiation therapy within the required time before starting the study - You are in adequate general health **You may NOT be eligible if...** - You have had major surgery within 28 days or chemotherapy within 14 days before starting - You have an active serious infection - You have another active cancer - You have significant heart disease Talk to your doctor to see if this trial is right for you.